A5019875049- Ocular Diseases and Behçet’s Syndrome
- Autoimmune and Inflammatory Disorders Research
- Systemic Lupus Erythematosus Research
- Inflammasome and immune disorders
- Rheumatoid Arthritis Research and Therapies
- Retinal and Optic Conditions
- Otitis Media and Relapsing Polychondritis
- Vasculitis and related conditions
- Spondyloarthritis Studies and Treatments
- Chronic Lymphocytic Leukemia Research
- Psoriasis: Treatment and Pathogenesis
- Pericarditis and Cardiac Tamponade
- Eosinophilic Disorders and Syndromes
- IL-33, ST2, and ILC Pathways
- Immune Cell Function and Interaction
- Hepatitis C virus research
- Kawasaki Disease and Coronary Complications
- Lymphoma Diagnosis and Treatment
- Hepatitis B Virus Studies
- Adolescent and Pediatric Healthcare
- Urticaria and Related Conditions
- Immunodeficiency and Autoimmune Disorders
- Streptococcal Infections and Treatments
- Biosimilars and Bioanalytical Methods
- Eosinophilic Esophagitis
University of Bari Aldo Moro
2016-2025
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2025
Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari
2024
University of Siena
2016-2021
University of L'Aquila
2021
University of Campania "Luigi Vanvitelli"
2021
University of Padua
2021
Center for Rheumatology
2017-2021
Vita-Salute San Raffaele University
2021
Istituti di Ricovero e Cura a Carattere Scientifico
2021
Background and objectives: few studies have reported the drug retention rate (DRR) of biologic drugs in juvenile idiopathic arthritis (JIA), none them has specifically investigated DRR interleukin (IL)-1 inhibitors on systemic JIA (sJIA). This study aims to describe IL-1 evaluate predictive factors survival based data from a real-world setting concerning sJIA. Methods: Medical records sJIA patients treated with anakinra (ANA) canakinumab (CAN) were retrospectively analyzed 15 Italian...
Aims Novel therapies are needed for recurrent pericarditis, particularly when corticosteroid dependent and colchicine resistant. Based on limited data, interleukin-1 blockade with anakinra may be beneficial. The aim of this multicentre registry was to evaluate the broader effectiveness safety in a ‘real world’ population. Methods results This enrolled consecutive patients pericarditis who were resistant treated anakinra. primary outcome recurrence rate after treatment. Secondary outcomes...
Mepolizumab proved to be an efficacious treatment for eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the randomized, controlled MIRRA trial. In few recently reported studies, successful real-life experiences approved treating severe asthma (100 weeks) were observed. We undertook this study assess effectiveness and safety mepolizumab 100 large European EGPA cohort.We included all patients treated recruiting centers 2015-2020. Treatment response was...
Colorectal cancer (CRC) is a type of tumor caused by the uncontrolled growth cells in mucosa lining last part intestine. Emerging evidence underscores an association between CRC and gut microbiome dysbiosis. The high mortality rate this has made it necessary to develop new early diagnostic methods. Machine learning (ML) techniques can represent solution evaluate interaction intestinal microbiota host physiology. Through explained artificial intelligence (XAI) possible individual...
Background: Interleukin (IL)-1 plays a crucial role in the pathogenesis of Adult onset Still's disease (AOSD). Objectives: To evaluate efficacy and safety anakinra (ANA) canakinumab (CAN) large group AOSD patients. Methods: Data on clinical, serological features, concomitant treatments were retrospectively collected at baseline after 3, 6, 12 months from patients (Yamaguchi criteria) referred by 18 Italian centers. Pouchot's score was used to severity. Results: One hundred forty treated with...
European and Asian studies report conflicting data on the risk of hepatitis B virus (HBV) reactivation in rheumatologic patients with a previously resolved HBV (prHBV) infection undergoing long-term biologic therapies. In this patient category, safety different immunosuppressive therapies, including rituximab, was assessed. A total 1218 Caucasian patients, admitted consecutively as outpatients between 2001 2012 taking underwent evaluation anti-HCV markers well liver amino transferases every...
Background: interleukin (IL)-1 inhibitors have been suggested as possible therapeutic options in a large number of old and new clinical entities characterized by an IL-1 driven pathogenesis. Objectives: to perform nationwide snapshot the on-label off-label use anakinra (ANA) canakinumab (CAN) for different conditions both children adults. Methods: we retrospectively collected demographic, clinical, data from adult pediatric patients treated with January 2008 July 2016. Results: 526 treatment...
The prevalence of sarcopenia in rheumatic diseases has been evaluated single using various diagnostic approaches, generating conflicting data on the pathogenetic mechanism(s). Herein, we both muscle mass index (MMI) and strength to assess presarcopenia patients with rheumatoid arthritis (RA), psoriatic (PsA), ankylosing spondylitis (AS). Moreover, possible impact disease/patient-related characteristics, therapeutic regimens, nutritional aspects sarcopenia. present study included 168 genders,...
To evaluate the effectiveness and safety of secukinumab in patients with a mucosal articular Behçet's phenotype resistant to conventional biologic treatment.A multicentre retrospective study was performed on 15 syndrome fulfilling International Criteria for Disease refractory treatment colchicine, disease-modifying antirheumatic drugs at least one antitumour necrosis factor-α agent. Minimum follow-up set 6 months. Six polyarticular involvement were treated 300 mg/month, while all other cases...
Objective To develop and validate the evidence-based consensus-based Behçet’s Syndrome Overall Damage Index (BODI). Methods Starting from 120 literature-retrieved preliminary items, BODI underwent multiple Delphi rounds with an international multidisciplinary panel consisting of rheumatologists, internists, ophthalmologists, neurologists, patient delegates until consensus was reached on final content. The validated in a cross-sectional multicentre cohort 228 patients syndrome (BS) through...
Rheumatoid arthritis (RA) patients on JAK inhibitors (JAKi) have an increased HZ risk compared to those biologic DMARDs (bDMARDs). Recently, the Adjuvanted Recombinant Zoster Vaccine (RZV) became available worldwide, showing good effectiveness in with inflammatory arthritis. Nevertheless, direct evidence of immunogenicity such a vaccine JAKi or anti-cellular bDMARDs is still lacking. This prospective study aimed assess RZV and safety RA receiving that are known lead impaired immune response....
Objectives Patients with rheumatoid arthritis (RA) and interstitial lung disease (ILD) have increased mortality compared to the general population factors capable of predicting RA-ILD long-term clinical outcomes are lacking. In oncology, radiomics allows quantification tumour phenotype by analysing characteristics medical images. Using specific software, it is possible segment organs on high-resolution computed tomography (HRCT) images extract many features that may uncover not detected...